Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is China Resources Pharmaceutical Group Debt-to-EBITDA?
China Resources Pharmaceutical GroupSTU:640 69 Debt-to-EBITDA is 4.21 as of Dec. 2025, which is 17% above its 10-year median of 3.60. GuruFocus rates STU:640 with a GF Score™ of 69/100 and a GF Value™ of €0.63 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 683 Drug Manufacturers companies, China Resources Pharmaceutical Group ranks worse than 75.7% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
STU:640'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.31 Med: 3.6 Max: 4.17
Current: 4.07
During the past 13 years, the highest Debt-to-EBITDA Ratio of China Resources Pharmaceutical Group was 4.17. The lowest was 2.31. And the median was 3.60.
STU:640's Debt-to-EBITDA is ranked worse than 75.7% of 683
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs STU:640: 4.07
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
China Resources Pharmaceutical Group Debt-to-EBITDA Related Terms
China Resources Pharmaceutical Group Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
China Resources Pharmaceutical Group (STU:640) has a Debt-to-EBITDA of 4.21 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Resources Pharmaceutical Group. This is 17% above median its historical median of 3.60. Over the past decade, China Resources Pharmaceutical Group's Debt-to-EBITDA has ranged from 2.31 to 4.17. According to the industry distribution chart, China Resources Pharmaceutical Group ranks #517 out of 683 companies in the Drug Manufacturers industry, placing it in the top 75.7%.
Is China Resources Pharmaceutical Group's Debt-to-EBITDA too high?
China Resources Pharmaceutical Group's current Debt-to-EBITDA of 4.21 is 17% above median its 10-year median of 3.60. Over the past 10 years, this metric has ranged from a low of 2.31 to a high of 4.17. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. China Resources Pharmaceutical Group's value of 4.21 is 158.3% above this industry median. Based on the distribution chart, China Resources Pharmaceutical Group ranks #517 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Resources Pharmaceutical Group has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Resources Pharmaceutical Group ranks #517 out of 683 companies for Debt-to-EBITDA. This places China Resources Pharmaceutical Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. China Resources Pharmaceutical Group's value of 4.21 is 158.3% above this benchmark. Historically, China Resources Pharmaceutical Group's own Debt-to-EBITDA has ranged from 2.31 to 4.17 over the past decade. While the company's 10-year median is 3.60 vs. the industry median of 1.63, China Resources Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Pharmaceutical Group's current Debt-to-EBITDA of 4.21 is 158.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Resources Pharmaceutical Group. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Pharmaceutical Group's current Debt-to-EBITDA is 4.21, which is 17% above median its own 10-year median of 3.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.63, compared to a current price of €0.53 — trading 16.7% below its estimated fair value. The current Debt-to-EBITDA is 4.21, which is 17% above median its 10-year median of 3.60 and 158.3% above the Drug Manufacturers industry median of 1.63. China Resources Pharmaceutical Group's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current Debt-to-EBITDA is 4.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.53 is trading 16.7% below its estimated GF Value™ of €0.63.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for STU:640:
Debt-to-EBITDA: 4.21 (17% above median its 10-year median of 3.60)
GF Value™: €0.63 vs. price of €0.53 (16.7% below fair value)
Industry Position: 158.3% above the Drug Manufacturers median (#517 of 683)
No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
69GF Score
Get the complete analysis for STU:640
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:640 has been successfully added to your 
